Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis.

MLA

Kristen, Arnt V., et al. “Evaluation of the Clinical Use of Midregional Pro-Atrial Natriuretic Peptide (MR-ProANP) in Comparison to N-Terminal pro-B-Type Natriuretic Peptide (NT-ProBNP) for Risk Stratification in Patients with Light-Chain Amyloidosis.” International Journal of Cardiology, vol. 176, no. 3, Oct. 2014, pp. 1113–15. EBSCOhost, https://doi.org/10.1016/j.ijcard.2014.07.106.

APA

Kristen, A. V., Biener, M., Hegenbart, U., Hardt, S., Schnabel, P. A., Röcken, C., Schonland, S. O., Katus, H. A., & Giannitsis, E. (2014). Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis. International Journal of Cardiology, 176(3), 1113–1115. https://doi.org/10.1016/j.ijcard.2014.07.106

Chicago

Kristen, Arnt V., Moritz Biener, Ute Hegenbart, Stefan Hardt, Philipp A. Schnabel, Christoph Röcken, Stefan O. Schonland, Hugo A. Katus, and Evangelos Giannitsis. 2014. “Evaluation of the Clinical Use of Midregional Pro-Atrial Natriuretic Peptide (MR-ProANP) in Comparison to N-Terminal pro-B-Type Natriuretic Peptide (NT-ProBNP) for Risk Stratification in Patients with Light-Chain Amyloidosis.” International Journal of Cardiology 176 (3): 1113–15. doi:10.1016/j.ijcard.2014.07.106.